Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
复制标题
DOI：
10.1200/jco.18.00622
复制
发表时间：
2019-05-20
影响因子：
45.3
通讯作者：
Choy, Hak
中科院分区：
文献类型：
--
作者：
Bezjak, Andrea;Paulus, Rebecca;Choy, Hak
中心型早期非小细胞肺癌（NSCLC）患者接受大剂量消融性放射治疗的毒性风险较高。NRG Oncology/RTOG 0813是一项I/II期研究，旨在确定立体定向体部放疗（SBRT）治疗中心部位NSCLC的最大耐受剂量（MTD）、疗效和毒性。
PURPOSE Patients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC.MATERIALS AND METHODS Medically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (